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Objective: Reduced eﬃcacy has been reported in the elderly; it may be a consequence of an age-
dependent decline in estimated glomerular ﬁltration rate (eGFR) rather than ageing per se. We sought
to determine the impact of these 2 parameters, as well as sex and baseline body mass index (BMI),
on the eﬃcacy and safety of canagliﬂozin, a sodium glucose co-transporter 2 inhibitor, in people with
type 2 diabetes.
Methods: Data were pooled from 6 randomized, double-blind, placebo-controlled studies (18 or 26 weeks;
N=4053). Changes in glycated hemoglobin (A1C) and systolic blood pressure (BP) from baseline with
canagliﬂozin 100 mg and 300 mg and placebo were evaluated in subgroups by sex, baseline BMI, base-
line age and baseline eGFR. Safety was assessed by reports of adverse events.
Results: Placebo-subtracted reductions in A1C with canagliﬂozin 100 mg and 300mg were similar in men
and women. A1C reductions with canagliﬂozin were seen across BMI subgroups and in participants aged
<65 years and ≥65 years. Signiﬁcantly greater placebo-subtracted reductions in A1C were seen with both
canagliﬂozin doses in participants with higher baseline eGFR (≥90 mL/min/1.73 m2). Reductions in sys-
tolic BP were seen with canagliﬂozin across subgroups of sex, BMI, age and eGFR. A1C reductions with
canagliﬂozin were similar for participants aged <65 or ≥65 years who had baseline eGFR ≥60 mL/min/
1.73 m2 and were smaller in older than in younger participants with baseline eGFR 45 to <60 mL/min/
1.73 m2. The overall incidence of adverse events was similar across treatment groups regardless of sex,
baseline BMI, baseline age or baseline eGFR.
Conclusions: Canagliﬂozin improved glycemic control, reduced BP andwas generally well tolerated in people
with type 2 diabetes across a range of ages, BMIs and renal functions.
© 2015 Canadian Diabetes Association.
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Objectif : Une réduction de l’eﬃcacité a été signalée chez les personnes âgées. Cette réduction peut être
la conséquence d’un déclin de l’estimation des débits de ﬁltration glomérulaire (eDFG) lié à l’âge plutôt
que le vieillissement en soi. Nous avons cherché à déterminer les répercussions de ces 2 paramètres, ainsi
que celles du sexe et des indices de masse corporelle (IMC) initiaux, sur l’eﬃcacité et l’innocuité de la
canagliﬂozine, un inhibiteur du cotransporteur sodium-glucose de type 2, chez les personnes souffrant
du diabète sucré de type 2.
Méthodes : Les données de 6 études comparatives contre placebo, à répartition aléatoire et à double insu
(18 ou 26 semaines; N=4053) ont été regroupées. Nous avons évalué en sous-groupes par sexe, IMC initial,
âge et eDFG les changements dans les valeurs initiales de l’hémoglobine glyquée (A1c) et de la pression
artérielle (PA) systolique entre les personnes qui prenaient 100 mg et 300 mg de canagliﬂozine, et les
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personnes qui prenaient le placebo. Les déclarations d’événements indésirables ont permis l’évaluation
de l’innocuité.
Résultats : Les réductions soustraites du placebo dans les concentrations d’A1C étaient similaires chez
les hommes et les femmes qui prenaient 100 mg et 300 mg de canagliﬂozine. Nous avons observé des
réductions de la concentration d’A1C chez les personnes qui prenaient de la canagliﬂozine dans tous les
sous-groupes par IMC et chez les participants de <65 ans et de ≥65 ans. Nous avons aussi observé des
réductions soustraites du placebo signiﬁcativement plus grandes dans les concentrations d’A1C pour les
deux doses de canagliﬂozine chez les participants ayant une eDFG initiale plus élevée (≥90 ml/min/
1,73 m2). Nous avons observé des réductions de la PA systolique lors de la prise de canagliﬂozine parmi
tous les sous-groupes par sexe, IMC, âge et eDFG. Les réductions de la concentration d’A1c lors de la prise
de canagliﬂozine étaient similaires chez les participants de <65 ans ou de ≥65 ans qui avaient une eDFG
initiale ≥60 ml/min/1,73 m2 et étaient plus petites chez les participants plus âgés que chez les partici-
pants plus jeunes ayant une eDFG intiale de 45 à <60ml/min/1,73 m2. L’incidence globale des événements
indésirables était similaire dans tous les groupes de traitement, quels que soient le sexe, l’IMC initial, l’âge
ou l’eDFG.
Conclusions : La canagliﬂozine améliorait la régulation glycémique, réduisait la PA et était généralement
bien tolérée par les personnes souffrant du diabète de type 2 à divers âges, IMC et fonctionnements rénaux.
© 2015 Canadian Diabetes Association.
Introduction
Canagliﬂozin is a sodium glucose co-transporter 2 (SGLT2) inhibi-
tor developed to treat adults with type 2 diabetes (1–13).
Canagliﬂozin inhibits renal glucose reabsorption by lowering the
renal threshold for glucose (RTG), thus reducing reabsorption of ﬁl-
tered glucose and increasing urinary glucose excretion (UGE), which
results in lowered plasma glucose levels and a net caloric loss
(1,14–16). Previous studies have reported a UGE of approximately
80 to 120 grams of glucose per day with canagliﬂozin treatment
in people with type 2 diabetes (14,17,18).
In Phase 3 studies, canagliﬂozin provided reductions in glycated
hemoglobin (A1C), body weight and systolic blood pressure (BP),
and was generally well tolerated across a broad range of partici-
pants with type 2 diabetes (2–13). Clinical characteristics, such as
sex, age and body mass index (BMI), may affect patients’ responses
to antihyperglycemic agent (AHA) therapy and should be consid-
ered when determining optimal treatment options for the man-
agement of type 2 diabetes. Canagliﬂozin has demonstrated greater
effects in lowering A1C levels in participants with type 2 diabetes
<65 years of age compared with participants 65 years of age or older
(19). The rate of UGE is proportional to the glomerular ﬁltration rate
(GFR) and plasma glucose level (15,20), so the effect of canagliﬂozin
on increasing UGE is expected to be attenuated in participants with
lower GFRs. Consistent with this, the eﬃcacy of canagliﬂozin has
been shown to be dependent on renal function status (4,21). Thus,
the differences in glycemic eﬃcacy observed with canagliﬂozin
between older and younger participants may be due to differ-
ences in baseline GFR. Of note, although GFR is considered to be
the best measure of renal function, estimated GFR (eGFR) is typi-
cally used in clinical practice because of the diﬃculties and costs
associated with obtaining actual GFR measurements (22).
In this analysis, the eﬃcacy of canagliﬂozin in improving A1C
and systolic BP and the safety of canagliﬂozin were assessed in sub-
groups by sex, baseline BMI, baseline age and baseline eGFR using
pooled data from 6 randomized, double-blind, placebo-controlled,
Phase 3 studies in people with type 2 diabetes.
Methods
Study design, patient populations and treatments
This post hoc analysis was based on pooled data from 6 double-
blind, placebo-controlled, Phase 3 studies of 18 or 26 weeks’ dura-
tion in people with type 2 diabetes (N=4053), including studies of
canagliﬂozin as monotherapy (2), add-on to metformin (9), add-on
to metformin plus sulphonylurea (10), add-on to metformin plus
pioglitazone (13), and the CANagliﬂozin cardioVascular Assess-
ment Study (CANVAS) add-on to sulphonylurea and add-on to insulin
substudies (23,24) (Table 1). In each study, participants were ran-
domized to receive canagliﬂozin 100mg or 300mg or placebo once
daily. Data for participants in the high glycemic substudy (base-
line A1C >10.0% [86mmol/mol] and ≤12.0% [108mmol/mol]) of the
monotherapy study (not placebo controlled) and the sitagliptin arm
of the add-on to metformin study were not included in this analy-
Table 1
Study design and participant population
Inclusion criteria Participants contributing
data to pooled analysis, na
Study Time pointb Age, y eGFR,
mL/min/1.73 m2
A1C, % PBO CANA
100 mg
CANA
300 mg
Total
Monotherapy 26 weeks ≥18 and ≤80 ≥50 ≥7.0 and ≤10.0 191 194 197 582
Add-on to MET 26 weeks ≥18 and ≤80 ≥55 ≥7.0 and ≤10.5 183 368 367 918
Add-on to MET+SU 26 weeks ≥18 and ≤80 ≥55 ≥7.0 and ≤10.5 155 157 156 468
Add-on to MET+PIO 26 weeks ≥18 and ≤80 ≥55 ≥7.0 and ≤10.5 115 113 114 342
CANVAS add-on to insulin substudy 18 weeks ≥30c ≥30 ≥7.0 and ≤10.5 532 540 557 1629
CANVAS add-on to SU substudy 18 weeks ≥30c ≥30 ≥7.0 and ≤10.5 39 39 36 114
Total, N 1215 1411 1427 4053
A1C, glycated hemoglobin; CANA, canagliﬂozin; CANVAS, CANagliﬂozin cardioVascular Assessment Study; CV, cardiovascular; eGFR, estimated glomerular ﬁltration rate; MET,
metformin; PBO, placebo; PIO, pioglitazone; SU, sulphonylurea.
a Data for participants with baseline eGFR <45 mL/min/1.73 m2 were excluded from the analysis.
b Assessment time point.
c ≥30 years for patients with a history of CV disease or ≥50 years for patients with presence of CV risk factors.
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sis. Data for participants with baseline eGFR <45 mL/min/1.73 m2
were also excluded from this pooled analysis because canagliﬂozin
is not indicated for use in these patients (25).
Eligible participants must have had inadequately controlled
type 2 diabetes at screening and at the start of the placebo run-in
period while on the protocol-speciﬁed background AHA therapy.
Key inclusion criteria for most studies included A1C levels ≥7.0%
(53mmol/mol) and ≤10.5% (91mmol/mol) at screening and repeated
fasting plasma glucose (FPG) ≥15.0 mmol/L (270mg/dL) during the
pretreatment phase (Table 1). Common exclusion criteria included
histories of type 1 diabetes; severe renal impairment; myocardial
infarction, unstable angina, revascularization procedure or cere-
brovascular accident with 3 months of screening; and uncon-
trolled hypertension. Details of the study design, as well as
randomization and blinding, and glycemic rescue therapy have pre-
viously been reported for the individual studies included in this
pooled dataset (2,9,10,13,23,24,26).
All studies included in this analysis were conducted in accor-
dance with ethical principles that comply with the Declaration of
Helsinki and were consistent with good clinical practices and appli-
cable regulatory requirements. Study protocols and amendments
were approved by institutional review boards and independent ethics
committees at participating institutions. All participants provided
written informed consent prior to participation in the studies.
Study endpoints and assessments
The primary endpoint for each study was the change in A1C from
baseline at the primary assessment time point (week 18 for CANVAS
substudies and week 26 for other studies). In this post hoc analy-
sis, changes in A1C and systolic BP from baseline were evaluated
in subgroups of participants based on sex (men [n=2301] andwomen
[n=1752]); baseline BMI (<25 kg/m2 [n=353], 25 to <30 kg/m2
[n=1148], 30 to <35 kg/m2 [n=1298] and ≥35 kg/m2 [n=1250]); base-
line age (<65 years [n=2905] and ≥65 years [n=1148]); and base-
line eGFR (≥90 mL/min/1.73 m2 [n=1369], 60 to <90 mL/min/
1.73 m2 [n=2295] and 45 to <60 mL/min/1.73 m2 [n=389]). Baseline
eGFR was calculated according to the Modiﬁcation of Diet and Renal
Disease Study (MDRD) equation (27,28). An additional explor-
atory analysis examined changes in A1C and systolic BP as a func-
tion of age and baseline eGFR. A separate analysis evaluated the
change in A1C in participants with baseline eGFR <45 mL/min/
1.73m2. Safety and tolerability were assessed based on adverse event
(AE) reports. The overall incidence of AEs, as well as the incidence
of speciﬁcally selected AEs related to the mechanism of action of
canagliﬂozin, including genital mycotic infections, urinary tract infec-
tions (UTIs) and AEs related to osmotic diuresis (e.g. pollakiuria, poly-
uria) and volume depletion (e.g. postural dizziness, orthostatic
hypotension) were evaluated. A comprehensive analysis of safety
with canagliﬂozin has been reported previously (29).
Statistical analyses
Eﬃcacy analyses were conducted using the modiﬁed intent-to-
treat analysis set, which included all randomized participants who
received ≥1 dose of double-blind study drug. Eﬃcacy data were ana-
lyzed according to randomized treatment assignment using the last
observation carried forward (LOCF) approach to imputemissing data;
for participants who received glycemic rescue therapy, the last
postbaseline value prior to initiation of rescue therapy was used
for analysis. An analysis of covariance (ANCOVA) model, with treat-
ment and study as factors and the respective baseline value for each
endpoint as a covariate, was used to assess primary endpoints. The
least squares (LS) mean differences between groups and 2-sided 95%
conﬁdence intervals (CIs) were estimated. No formal hypothesis
testing was conducted for the subgroup analyses; therefore, no
P values are reported. Safety analyses included all reported AEs,
regardless of rescue therapy, and included all randomized partici-
pants who received ≥1 dose of double-blind study drug.
Results
Participant disposition and baseline characteristics
Of the 4053 participants in the modiﬁed intent-to-treat popu-
lation with baseline eGFR ≥45 mL/min/1.73 m2, 3601 (88.8%) com-
pleted the respective primary assessment period. Baseline
demographic and disease characteristics were generally similar
across treatment groups in the overall population (Table 2). The
majority of participants were men (56.8%) and <65 years of age
(71.7%). A similar proportion of participants had baseline BMI 25
to <30 kg/m2 (28.3%), 30 to <35 kg/m2 (32.1%) and ≥35 kg/m2 (30.9%);
a small proportion had baseline BMI <25 kg/m2 (8.7%). Most par-
ticipants had baseline eGFR 60 to <90 mL/min/1.73 m2 (56.6%) or
eGFR ≥90 mL/min/1.73 m2 (33.8%); 9.6% of participants had
Table 2
Baseline demographic and disease characteristics (overall population)a
Characteristic PBO
(n=1215)
CANA 100 mg
(n=1411)
CANA 300 mg
(n=1427)
Total
(N=4053)
Sex, n (%)
Men 714 (59) 793 (56) 794 (56) 2301 (57)
Women 501 (41) 618 (44) 633 (44) 1752 (43)
Age, years 59.1±9.3 58.6±9.7 58.8±9.5 58.8±9.5
Race, n (%)b
White 910 (75) 1037 (73) 1071 (75) 3018 (74)
Black or African American 41 (3) 54 (4) 64 (4) 159 (4)
Asian 169 (14) 184 (13) 183 (13) 536 (13)
Otherc 95 (8) 136 (10) 109 (8) 340 (8)
A1C, % (mmol/mol) 8.1±0.9 (65±9.8) 8.1±0.9 (65±9.8) 8.1±0.9 (65±9.8) 8.1±0.9 (65±9.8)
FPG, mmol/L (mg/dL) 9.4±2.5 (169.4±45.0) 9.4±2.5 (169.4±45.0) 9.4±2.6 (169.4±46.8) 9.4±2.5 (169.4±45.0)
BMI, kg/m2 32.7±6.5 32.7±6.4 32.6±6.4 32.7±6.4
eGFR, mL/min/1.73 m2 82.1±19.4 84.1±19.0 83.2±19.4 83.2±19.3
Duration of type 2 diabetes,
years
11.4±8.1 11.0±8.0 11.0±7.9 11.1±8.0
A1C, glycated hemoglobin; BMI, body mass index; CANA, canagliﬂozin; eGFR, estimated glomerular ﬁltration rate; FPG, fasting plasma glucose; PBO, placebo; SD, standard
deviation.
a Data are mean ± SD unless otherwise indicated.
b Percentages may not total 100% due to rounding.
c Includes American Indian or Alaska Native, Native Hawaiian or other Paciﬁc Islander, multiple, not reported, other and unknown.
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baseline eGFR 45 to <60mL/min/1.73m2. Baseline demographic and
disease characteristics in subgroups based on age at baseline are
shown in the Supplementary Table A1. Participants aged ≥65 years
generally had longer known duration of type 2 diabetes and lower
BMI and eGFR values at baseline than participants aged <65 years.
Glycemic eﬃcacy
Across subgroups, canagliﬂozin 100 mg and 300 mg provided
clinically meaningful, dose-related reductions in A1C that were con-
sistently larger than those observed with placebo, regardless of sex,
baseline BMI, baseline age or baseline eGFR (Figure 1). The 95% CIs
for changes in A1C overlap between subgroups, based on sex, BMI
or age, indicating no differences in A1C lowering related to sex, BMI
or age. Participants with baseline eGFR ≥90mL/min/1.73m2 had sig-
niﬁcantly greater A1C reductions compared with participants with
lower baseline eGFR values.
Sex
Canagliﬂozin 100 mg and 300 mg were associated with
placebo-subtracted LS mean reductions from baseline in A1C
levels that were similar in men (−0.72% [−7.9 mmol/mol] and
−0.84% [−9.2 mmol/mol], respectively) and women (−0.68%
[−7.4 mmol/mol] and −0.84% [−9.2 mmol/mol], respectively)
(Figure 2).
Body mass index
Placebo-subtracted reductions from baseline in A1C were gen-
erally similar across subgroups of baseline BMI with canagliﬂozin
100 mg and 300 mg (BMI <25 kg/m2: −0.74% [−8.1 mmol/mol] and
−0.78% [−8.5 mmol/mol]; 25 to <30 kg/m2: −0.67% [−7.3 mmol/
mol] and −0.82% [−9.0 mmol/mol]; 30 to <35 kg/m2: −0.71%
[−7.8 mmol/mol] and −0.83% [−9.1 mmol/mol]; ≥35 kg/m2: −0.73%
[−8.0 mmol/mol] and −0.91% [−9.9 mmol/mol], respectively)
(Figure 3).
Age
Placebo-subtracted reductions from baseline in A1C were seen
with canagliﬂozin 100mg and 300mg in participants aged <65 years
(−0.72% [−7.9 mmol/mol] and −0.88% [−9.6 mmol/mol], respec-
tively) and ≥65 years (−0.65% [−7.1 mmol/mol] and −0.76%
[−8.3mmol/mol], respectively) (Figure 4). Clinically meaningful A1C
reductions were seen with both canagliﬂozin doses in both age
groups.
Estimated glomerular ﬁltration rate
Larger, placebo-subtracted reductions from baseline in A1C were
seen with canagliﬂozin 100 mg and 300 mg in participants with
baseline eGFR ≥90 mL/min/1.73 m2 (−0.87% [−9.5 mmol/mol]
and −1.01% [−11.0mmol/mol], respectively) compared to those with
lower baseline eGFRs (eGFR 60 to <90 mL/min/1.73 m2: −0.63%
[−6.9 mmol/mol] and −0.80% [−8.7 mmol/mol]; 45 to <60 mL/min/
1.73 m2: −0.57% [−6.2 mmol/mol] and −0.61% [−6.7 mmol/mol],
respectively) (Figure 5). Participants with baseline eGFR
<45 mL/min/1.73 m2 (n=111) were not included in the pooled
subgroup analysis because canagliﬂozin is not indicated for use
in these patients (25). Among participants with baseline eGFR
<45mL/min/1.73m2, placebo-subtracted changes (95% CI) from base-
line in A1C with canagliﬂozin 100 mg and 300 mg were −0.02%
(−0.55, 0.51; −0.2 mmol/mol [−6.0, 5.6]) and −0.25% (−0.76, 0.26;
−2.7 mmol/mol [−8.3, 2.8]).
Age by estimated glomerular ﬁltration rate
Because a decline in eGFR may occur with aging, data were ana-
lyzed as a function of both age and eGFR. The majority of partici-
pants <65 years of age had baseline eGFR ≥90 mL/min/1.73 m2
(n=1214; 42%) or 60 to <90mL/min/1.73m2 (n=1522; 52%); 169 par-
ticipants (6%) had baseline eGFR 45 to <60mL/min/1.73 m2. Among
participants ≥65 years of age, most had baseline eGFR 60 to <90mL/
min/1.73 m2 (n=773; 67%); fewer participants had baseline eGFR
≥90 mL/min/1.73 m2 (n=155; 14%) or 45 to <60 mL/min/1.73 m2
(n=220; 19%). Absolute mean and median eGFR values were similar
across treatment groups in the age and eGFR subgroups (Figure 6);
older participants generally had lower baseline eGFR.
The impact of age on A1C lowering was attenuated within eGFR
subgroups (Figure 6). Placebo-subtracted changes from baseline in
A1C with canagliﬂozin 100 mg and 300 mg were similar for
older and younger participants in subgroups of baseline
eGFR ≥90 mL/min/1.73 m2 (<65 years: −0.86% [−9.4 mmol/mol]
–1.2% –0.8% –0.4% 0% 0.4% 0.8%
eGFR ≥90 mL/min/1.73 m2
eGFR 60 to <90 mL/min/1.73 m2
eGFR 45 to <60 mL/min/1.73 m2
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BMI 30 to <35 kg/m2
BMI 25 to <30 kg/m2
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CANA 100 mg CANA 300 mg
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Figure 1. Differences (95% CIs) between canagliﬂozin 100 mg and 300 mg vs. placebo in the change in A1C from baseline by subgroup (LOCF).
A1C, glycated hemoglobin; BMI, body mass index; CANA, canagliﬂozin; CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; LOCF, last observation carried forward;
PBO, placebo.
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Figure 2. Change in A1C levels by sex (LOCF).
A1C, glycated hemoglobin; CANA, canagliﬂozin; CI, conﬁdence interval; LOCF, last observation carried forward; LS, least squares; PBO, placebo; SE, standard error.
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Figure 3. Change in A1C by baseline BMI (LOCF).
A1C, glycated hemoglobin; BMI, body mass index; CANA, canagliﬂozin; CI, conﬁdence interval; LOCF, last observation carried forward; LS, least squares; PBO, placebo; SE,
standard error.
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A1C, glycated hemoglobin; CANA, canagliﬂozin; CI, conﬁdence interval; LOCF, last observation carried forward; LS, least squares; PBO, placebo; SE, standard error.
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and −1.03% [−11.3 mmol/mol]; ≥65 years: −0.98% [−10.7 mmol/mol]
and −0.84% [−9.2 mmol/mol], respectively) and eGFR 60 to
<90mL/min/1.73m2 (<65 years: −0.63% [−6.9mmol/mol] and −0.78%
[−8.5 mmol/mol]; ≥65 years: −0.62% [−6.8 mmol/mol] and −0.82%
[−9.0 mmol/mol], respectively). Among the small subgroup of par-
ticipants with baseline eGFR 45 to <60 mL/min/1.73 m2, placebo-
subtracted changes in A1C with canagliﬂozin 100 mg and300 mg
were −0.66% (−7.2 mmol/mol) and −0.75% (−8.2 mmol/mol), respec-
tively, in participants aged <65 years, and were −0.49% (−5.4 mmol/
mol) and −0.52% (−5.7mmol/mol), respectively, in participants aged
≥65 years.
Changes in blood pressure
Canagliﬂozin 100mg and 300mg provided dose-related reduc-
tions in systolic BP that were larger than those observedwith placebo
across most subgroups (Supplementary Figure A1). The 95% CIs for
changes in systolic BP overlap between subgroups based on sex, BMI,
age and eGFR, indicating that the reductions in systolic BP provided by
canagliﬂozin are not related to these baseline patient characteristics.
Because age and eGFRmay affect BP, changes in systolic BP were ana-
lyzed as a function of both age and eGFR (Supplementary Figure A2).
Across eGFR subgroups, placebo-subtracted changes from baseline in
systolic BPwith canagliﬂozin 100mg and 300mg ranged from −2.8 to
−5.6mmHg in patients aged <65 years and from −0.8 to −5.3mmHg
inpatients aged ≥65years. Therewasno clear trend in systolic BP reduc-
tion across subgroups; however, thewide CIsmake it diﬃcult to inter-
pret differences based on age and eGFR.
Safety
The overall incidence of AEs was similar across treatment groups
(60.2%, 60.9% and 58.9% with canagliﬂozin 100mg and 300mg and
placebo, respectively). The incidence of AEs leading to discontinu-
ation (3.3%, 4.3% and 2.6% with canagliﬂozin 100 mg and 300 mg
and placebo, respectively) and the incidence of serious AEs (4.0%,
3.9% and 4.7% with canagliﬂozin 100 mg and 300 mg and placebo,
respectively) were low and were similar across treatment groups.
The overall incidence of AEs with canagliﬂozin 100 mg and
300mg and placebo was generally similar in men (59.1%, 61.1% and
57.1%, respectively) and women (61.7%, 60.7% and 61.5%, respec-
tively) and across baseline BMI subgroups (BMI <25 kg/m2: 57.7%,
57.1% and 51.0%; 25 to <30 kg/m2: 55.5%, 55.9% and 59.1%; 30 to
<35 kg/m2: 59.4%, 60.8% and 58.1%; ≥35 kg/m2: 66.2%, 67.0% and
61.7%). A higher incidence of genital mycotic infections and osmotic
diuresis–related AEs (e.g. pollakiuria [increased urine frequency],
polyuria [increased urine volume]) was seenwith canagliﬂozin com-
pared with placebo in both men and women. Genital mycotic infec-
tions and osmotic diuresis–related AEs were more frequently
reported with canagliﬂozin in participants with BMI ≥35 kg/m2. The
incidence of UTIs was higher across treatment groups in women
compared with men and was low and similar across BMI sub-
groups. The incidence of AEs related to volume depletion (e.g. pos-
tural dizziness, orthostatic hypotension) was low and similar across
treatment groups in men and women and across BMI subgroups.
The incidence of any AE, including AEs leading to discontinua-
tion and serious AEs, was generally similar across treatment groups,
regardless of age or baseline eGFR (Table 3). Across treatment groups,
the incidence of serious AEs was generally higher in participants
with baseline eGFR 45 to <60 mL/min/1.73 m2 compared to those
with higher baseline eGFR (60 to <90 and ≥90 mL/min/1.73 m2),
regardless of age. The incidence of genital mycotic infections in men
and women was generally higher with canagliﬂozin than with
placebo across age and eGFR subgroups. The incidence of UTIs and
osmotic diuresis– and volume depletion–related AEs was gener-
ally low across treatment groups in the age and eGFR subgroups.
The incidence of osmotic diuresis–related AEs was generally lower
with canagliﬂozin compared with placebo, except in participants
aged <65 years with eGFR 45 to <60 mL/min/1.73 m2. The inci-
dence of volume depletion–related AEs was higher with both
canagliﬂozin doses compared with placebo in participants aged ≥65
years with eGFR 60 to <90 mL/min/1.73 m2 or 45 to <60 mL/min/
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Figure 6. Placebo-subtracted LS mean changes in A1C by age at baseline and baseline eGFR (LOCF).
A1C, glycated hemoglobin; CANA, canagliﬂozin; CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; LOCF, last observation carried forward; LS, least squares;
PBO, placebo; SE, standard error.
aUnit of mL/min/1.73 m2 for eGFR.
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Table 3
Summary of overall safety and selected adverse events by age and baseline eGFR
Participants <65 years, n (%)
eGFR ≥90 mL/min/1.73 m2 eGFR 60 to <90 mL/min/1.73 m2 eGFR 45 to <60 mL/min/1.73 m2
PBO
(n=338)
CANA 100 mg
(n=444)
CANA 300 mg
(n=432)
PBO
(n=465)
CANA 100 mg
(n=522)
CANA 300 mg
(n=535)
PBO
(n=61)
CANA 100 mg
(n=52)
CANA 300 mg
(n=56)
Any AE 194 (57.4) 283 (63.7) 268 (62.0) 267 (57.4) 305 (58.4) 325 (60.7) 42 (68.9) 27 (51.9) 32 (57.1)
AEs leading to discontinuation 6 (1.8) 14 (3.2) 12 (2.8) 10 (2.2) 12 (2.3) 17 (3.2) 3 (4.9) 1 (1.9) 4 (7.1)
AEs related to study druga 48 (14.2) 96 (21.6) 108 (25.0) 53 (11.4) 107 (20.5) 144 (26.9) 11 (18.0) 13 (25.0) 9 (16.1)
Serious AEs 14 (4.1) 15 (3.4) 14 (3.2) 14 (3.0) 14 (2.7) 14 (2.6) 11 (18.0) 1 (1.9) 8 (14.3)
Deaths 2 (0.6) 0 1 (0.2) 1 (0.2) 1 (0.2) 0 1 (1.6) 0 1 (1.8)
UTIs 13 (3.8) 21 (4.7) 18 (4.2) 12 (2.6) 24 (4.6) 16 (3.0) 1 (1.6) 2 (3.8) 1 (1.8)
Genital mycotic infections
Menb,c 1 (0.5) 11 (4.6) 9 (4.4) 3 (1.1) 10 (3.6) 20 (6.5) 0 0 1 (2.7)
Womend,e 10 (6.8) 33 (16.3) 38 (16.6) 2 (1.1) 31 (12.7) 29 (12.9) 0 3 (16.7) 3 (15.8)
Osmotic diuresis–related AEsf 2 (0.6) 24 (5.4) 19 (4.4) 1 (0.2) 19 (3.6) 20 (3.7) 1 (1.6) 1 (1.9) 0
Volume depletion–related AEsg 3 (0.9) 3 (0.7) 11 (2.5) 3 (0.6) 5 (1.0) 11 (2.1) 2 (3.3) 1 (1.9) 1 (1.8)
Participants ≥65 years, n (%)
eGFR ≥90 mL/min/1.73 m2 eGFR 60 to <90 mL/min/1.73 m2 eGFR 45 to <60 mL/min/1.73 m2
PBO
(n=42)
CANA 100 mg
(n=60)
CANA 300 mg
(n=53)
PBO
(n=243)
CANA 100 mg
(n=262)
CANA 300 mg
(n=268)
PBO
(n=66)
CANA 100 mg
(n=71)
CANA 300 mg
(n=83)
Any AE 23 (54.8) 32 (53.3) 35 (66.0) 153 (63.0) 163 (62.2) 161 (60.1) 37 (56.1) 40 (56.3) 48 (57.8)
AEs leading to discontinuation 1 (2.4) 2 (3.3) 3 (5.7) 8 (3.3) 12 (4.6) 15 (5.6) 3 (4.5) 6 (8.5) 10 (12.0)
AEs related to study druga 4 (9.5) 8 (13.3) 16 (30.2) 30 (12.3) 59 (22.5) 70 (26.1) 15 (22.7) 12 (16.9) 24 (28.9)
Serious AEs 1 (2.4) 4 (6.7) 1 (1.9) 11 (4.5) 17 (6.5) 11 (4.1) 6 (9.1) 6 (8.5) 8 (9.6)
Deaths 0 0 0 2 (0.8) 1 (0.4) 0 1 (1.5) 1 (1.4) 1 (1.2)
UTIs 1 (2.4) 2 (3.3) 3 (5.7) 10 (4.1) 8 (3.1) 13 (4.9) 0 3 (4.2) 3 (3.6)
Genital mycotic infections
Menc,h 0 0 4 (12.1) 0 10 (6.0) 10 (6.4) 0 1 (2.4) 3 (5.5)
Womene,i 1 (6.7) 3 (11.1) 2 (10.0) 0 11 (11.5) 14 (12.5) 1 (3.3) 2 (6.7) 2 (7.1)
Osmotic diuresis–related AEsf 0 1 (1.7) 0 1 (0.4) 11 (4.2) 6 (2.2) 0 0 2 (2.4)
Volume depletion–related AEsg 0 0 0 3 (1.2) 8 (3.1) 6 (2.2) 1 (1.5) 3 (4.2) 4 (4.8)
AE, adverse event; eGFR, estimated glomerular ﬁltration rate; CANA, canagliﬂozin; PBO, placebo; UTI, urinary tract infection.
a Possibly, probably or very likely related to the study drug, as assessed by investigator.
b eGFR ≥90 mL/min/1.73 m2: PBO, n=191; CANA 100 mg, n=241; CANA 300 mg, n=203; eGFR 60 to <90 mL/min/1.73 m2: PBO, n=278; CANA 100 mg, n=278; CANA 300 mg, n=310; eGFR 45 to <60 mL/min/1.73 m2: PBO, n=34;
CANA 100 mg, n=34; CANA 300 mg, n=37.
c Including balanitis, balanitis candida, balanoposthitis and genital infection fungal.
d eGFR ≥90 mL/min/1.73 m2: PBO, n=147; CANA 100 mg, n=203; CANA 300 mg, n=229; eGFR 60 to <90 mL/min/1.73 m2: PBO, n=187; CANA 100 mg, n=244; CANA 300 mg, n=225; eGFR 45 to <60 mL/min/1.73 m2: PBO, n=27;
CANA 100 mg, n=18; CANA 300 mg, n=19.
e Including pruritus genital, vaginal infection, vaginal inﬂammation, vulvitis, vulvovaginal burning sensation, vulvovaginal candidiasis, vulvovaginal discomfort, vulvovaginal dryness, vulvovaginal mycotic infection, vulvo-
vaginal pain, vulvovaginal pruritus and vulvovaginitis.
f Including dry mouth, dry throat, micturition urgency, nocturia, pollakiuria, polydipsia, polyuria, thirst and urine output increased.
g Including dehydration, dizziness postural, hypotension, orthostatic hypotension, orthostatic intolerance, presyncope and syncope.
h eGFR ≥90 mL/min/1.73 m2: PBO, n=27; CANA 100 mg, n=33; CANA 300 mg, n=33; eGFR 60 to <90 mL/min/1.73 m2: PBO, n=148; CANA 100 mg, n=166; CANA 300 mg, n=156; eGFR 45 to <60 mL/min/1.73 m2: PBO, n=36;
CANA 100 mg, n=41; CANA 300 mg, n=55.
i eGFR ≥90 mL/min/1.73 m2: PBO, n=15; CANA 100 mg, n=27; CANA 300 mg, n=20; eGFR 60 to <90 mL/min/1.73 m2: PBO, n=95; CANA 100 mg, n=96; CANA 300 mg, n=112; eGFR 45 to <60 mL/min/1.73 m2: PBO, n=30; CANA
100 mg, n=30; CANA 300 mg, n=28.
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1.73m2. The incidence of volume depletion–related AEs was similar
with canagliﬂozin 100mg and placebo and higher with canagliﬂozin
300 mg in participants aged <65 years with eGFR ≥90 mL/min/
1.73 m2 or 60 to <90 mL/min/1.73 m2. The overall incidence of AEs
in participants with baseline eGFR <45 mL/min/1.73 m2 with
canagliﬂozin 100mg and 300mg and placebo was 77.4%, 73.0% and
76.7%, respectively. The safety proﬁle of canagliﬂozin was similar
to that seen in patients with baseline eGFR ≥45mL/min/1.73m2, with
increased incidence of UTIs, genital mycotic infections and volume
depletion–related AEs compared with placebo.
Discussion
Findings from this post hoc analysis of pooled data from Phase 3
studies show that canagliﬂozin provides glycemic improvement
and reductions in BP compared with placebo in people with type 2
diabetes, regardless of sex, baseline BMI, baseline age or baseline eGFR.
Reductions in A1C were similar across subgroups by sex and baseline
BMI. Greater reductions in A1C were generally seen in younger par-
ticipants and in thosewith higher baseline eGFR, consistent with pre-
vious studies of canagliﬂozin (19,21). The reduced glycemic eﬃcacy
observed in older participants is likely related to lower baseline eGFR
because, among participants aged <65 years and ≥65 years of age, A1C
reductionswere similar in the baseline eGFR ≥90mL/min/1.73m2 and
eGFR 60 to <90mL/min/1.73m2 subgroups. In the small subgroup of
participantswith baseline eGFR 45 to <60mL/min/1.73m2, A1C reduc-
tionswere smaller in participants aged ≥65 years comparedwith those
aged <65 years; however, any apparent differencesmay be due to vari-
ability, given the small sample size of this subgroup, as evidenced by
the wide CIs observed for these comparisons.
Because of its mechanism of action, the eﬃcacy of canagliﬂozin is
expected to be dependent on the renal function status of partici-
pants. In a pooled analysis of data in participants with stage 3 chronic
kidney disease (eGFR ≥30 and <60 mL/min/1.73 m2), canagliﬂozin
100mg and 300mg provided greater reductions in A1C in the sub-
groups of participants with eGFR 45 to <60mL/min/1.73 m2 com-
pared to those with eGFR 30 to <45mL/min/1.73m2 (21). A separate
study (12) demonstrated that canagliﬂozin improves glycemic control
better than placebo in people with type 2 diabetes and eGFR ≥30 and
<50mL/min/1.73m2; reductions in A1Cwith canagliﬂozinwere smaller
than those reported inparticipantswithnormal ormildly impaired renal
function (3,7–11). These results are consistent with those seen in the
current analysis, which demonstrated that the A1C lowering response
to canagliﬂozin was reduced in participants with lower eGFR (45 to
<60mL/min/1.73m2) irrespective of age, albeit slightly less in partici-
pants aged ≥65 years than in those aged <65 years. Thus, eGFR, rather
than age, per se, largely determines the glycemic eﬃcacyof canagliﬂozin
in people with type 2 diabetes.
Canagliﬂozinwas generally well tolerated across subgroups by sex
and baseline BMI, baseline age and baseline GFR. The overall inci-
dence of AEs and AEs leading to discontinuation were similar across
treatment groups in all subgroups. The incidence of genital mycotic
infections andosmotic diuresis–relatedAEswas generally higher inmen
andwomen treatedwith canagliﬂozin vs. placebo, consistentwith pre-
vious studies (30); reports of genital mycotic infections and UTIs were
more common in women than in men, regardless of treatment. The
rate of genital mycotic infections with canagliﬂozin treatment tended
to increasewith increasing baseline BMIs. The incidence of serious AEs
was higher across treatment groups in participants with eGFR 45 to
<60mL/min/1.73m2, regardless of age. The incidence of genitalmycotic
infectionswas higherwith canagliﬂozin treatment in younger andolder
participants across eGFR subgroups. Although low overall, the inci-
dence of volume depletion–related AEswas higher with canagliﬂozin
than with placebo in older participants with lower baseline eGFR.
The studies included in this pooled analysis enrolled a large, diverse
population of participants with type 2 diabetes and a variety of base-
line characteristics that are typically encountered in a clinical setting.
A limitation of the analysis is the exclusion of data from participants
with baseline eGFR 30 to <45mL/min/1.73m2 because canagliﬂozin is
not indicated for use in people with baseline eGFR <45 mL/min/
1.73m2 (25). An additional limitation is the use of eGFR instead of direct
GFR measurements. Although the eGFR is often used as a more prac-
ticalmeansof determining renal function, themeasurement is less accu-
ratewhen eGFR is ≥60mL/min/1.73m2 (22). Furthermore, because age
is a variable in theMDRD equation used to calculate eGFR, age is a con-
founding factor (27,28). Last, longer-term assessment of the subgroup
factors inﬂuencing the glycemic eﬃcacy and safety of canagliﬂozin
would be helpful in evaluating the durability of canagliﬂozin treatment.
Overall, the ﬁndings from these subgroup analyses support
canagliﬂozin as a therapeutic option for people with type 2 diabetes,
including men and women across a broad range of ages, BMIs and
varying degrees of renal impairment.
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Appendix
Supplementary Table A1
Baseline demographic and disease characteristics by agea
<65 years ≥65 years
Characteristic PBO
(n=864)
CANA 100 mg
(n=1018)
CANA 300 mg
(n=1023)
PBO
(n=351)
CANA 100 mg
(n=393)
CANA 300 mg
(n=404)
Sex, n (%)
Men 503 (58) 553 (54) 550 (54) 211 (60) 240 (61) 244 (60)
Women 361 (42) 465 (46) 473 (46) 140 (40) 153 (39) 160 (40)
Age, years 54.9±7.4 54.2±7.5 54.5±7.4 69.5±3.9 69.8±3.9 69.7±4.0
Race, n (%)
White 618 (72) 710 (70) 737 (72) 292 (83) 327 (83) 334 (83)
Black/African American 31 (4) 46 (5) 55 (5) 10 (3) 8 (2) 9 (2)
Asian 142 (16) 157 (15) 150 (15) 27 (8) 27 (7) 33 (8)
Otherb 73 (8) 105 (10) 81 (8) 22 (6) 31 (8) 28 (7)
eGFR, mL/min/1.73 m2 85.9±19.6 87.8±18.9 87.4±19.3 72.8±15.4 74.4±15.7 72.5±15.3
eGFR ≥90 mL/min/1.73 m2, n (%) 338±39 444±44 432±42 42±12 60±15 53±13
eGFR 60 to <90 mL/min/1.73 m2, n (%) 465±54 522±51 535±52 243±69 262±67 268±66
eGFR 45 to <60 mL/min/1.73 m2, n (%) 61±7 52±5 56±5 66±19 71±18 83±21
BMI, kg/m2 32.9±6.8 33.0±6.7 32.8±6.6 32.2±5.5 31.9±5.6 32.1±5.9
Duration of type 2 diabetes, years 9.9±7.2 9.3±7.1 9.4±7.1 15.1±9.2 15.4±8.5 15.0±8.5
BMI, body mass index; CANA, canagliﬂozin; eGFR, estimated glomerular ﬁltration rate; PBO, placebo; SD, standard deviation.
a Data are mean ± SD unless otherwise indicated.
b Includes American Indian or Alaska Native, Native Hawaiian or other Paciﬁc Islander, multiple, not reported, other and unknown.
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Supplementary Figure A1. Differences (95% CIs) between canagliﬂozin 100 mg and 300 mg vs. placebo in the change in systolic BP from baseline by subgroup (LOCF).
BMI, body mass index; BP, blood pressure; CANA, canagliﬂozin; CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; LOCF, last observation carried forward;
PBO, placebo.
Supplementary Figure A2. Placebo-subtracted LS mean changes in systolic BP by age at baseline and baseline eGFR (LOCF).
BP, blood pressure; CANA, canagliﬂozin; CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; LOCF, last observation carried forward; LS, least squares; PBO,
placebo.
aUnit of mL/min/1.73 m2 for eGFR.
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